Antibody Heterodimer Identification with Deglycosylated SEC-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing analytical methods struggle to accurately differentiate and quantify heterodimers in co-formulated monoclonal antibody (mAb) drug products due to their low abundance and similar biophysical properties, which complicates formulation development and quality control.
Innovation Solution
A method involving deglycosylation followed by size exclusion chromatography and nano-electrospray ionization mass spectrometry is employed to identify and quantify multimers in antibody preparations, using a splitter to connect the chromatography system with both mass spectrometry and ultraviolet detection, and incorporating immunodepletion to simplify complex samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If size exclusion chromatography with UV detection is used for dimer analysis, then the method is simple and widely applicable, but it lacks the specificity to differentiate various hetero- and homodimer species
Solution Approach 1:
The patent combines size exclusion chromatography (SEC) with mass spectrometry (MS) detection to create a hybrid analytical system. The SEC column separates dimer species based on size, while the mass spectrometer provides precise mass measurements to differentiate between homodimers and heterodimers with similar biophysical properties. This merging of separation and detection functions resolves the contradiction by maintaining operational simplicity while achieving high specificity.
Solution Approach 2:
The patent introduces an intermediary sample preparation step involving deglycosylation treatment before SEC-MS analysis. This pre-treatment modifies the glycan structures of antibodies, reducing heterogeneity in molecular weight and improving the separation resolution of dimer species. The intermediary step enhances the effectiveness of the SEC-MS system in differentiating dimer types without complicating the overall methodology.
2Productivity
If direct analysis is performed without isolation, then the method is more efficient and requires smaller sample amounts, but the low abundance of heterodimers makes detection challenging
Solution Approach 1:
The patent applies preliminary action through deglycosylation treatment of the antibody sample before SEC-MS analysis. This pre-treatment modifies the glycan structures, which improves the mass-to-charge ratio and enhances the detectability of heterodimers at low abundances. The preliminary modification prepares the sample to be more amenable to sensitive MS detection without requiring prior isolation or concentration steps.
Solution Approach 2:
The patent utilizes parameter changes in the mass spectrometry detection mode, specifically employing high-resolution mass spectrometry with optimized scan parameters to detect low-abundance heterodimers. By adjusting the mass resolution and scan speed parameters, the system achieves sufficient sensitivity to detect heterodimers directly in co-formulated samples without prior isolation, maintaining both efficiency and detection precision.
3Measurement precision
If high-resolution mass spectrometry is used to differentiate dimers with close molecular weights, then differentiation accuracy improves, but the complexity of the analysis increases
Solution Approach 1:
The patent segments the analysis into distinct functional components: (1) sample preparation with deglycosylation treatment, (2) size exclusion chromatography separation, and (3) mass spectrometry detection. This segmentation allows each component to be optimized independently - the SEC column handles separation, while the MS system focuses on precise mass measurement. The modular approach reduces overall system complexity by dividing the analysis into manageable stages rather than requiring a single complex instrument.
Solution Approach 2:
The patent employs a universal sample preparation approach using deglycosylation treatment that applies to all antibody samples regardless of specific application. This multi-functional pre-treatment improves the performance of both SEC and MS detection simultaneously, making the analysis system more versatile and less complex. The same preparation step enhances separation resolution and mass differentiation capability without requiring application-specific optimizations.
Data Source
AI summary
The present disclosure generally pertains to methods for characterizing dimers in an antibody co-formulation. In particular, the present disclosure pertains to the use of high-throughput size exclusion chromatography coupled to low-resolution mass spectrometry, deglycosylation, and immunodepletion to differentiate dimers of similar sizes.